Informatics Tools for Pharmacogenomic Discovery using Practice-based Data

描述（由申请人提供）：大型电子医疗记录（EMR）的临床实施快速增长，导致观察性研究的密集纵向数据集的可用性空前扩大。最近，巨大的努力已经将EMR数据库与存档的生物材料联系起来，以加速个性化医疗的研究。EMR连锁DNA生物库已经确定了导致疾病风险的常见和罕见遗传变异。一个尚未被广泛探索的有吸引力的愿景是使用EMR相关生物库进行药物基因组学研究，确定遗传变异与药物疗效和毒性之间的关联。EMR中包含的数据的纵向性质使其成为量化药物结局（疗效和毒性）的理想选择。目前正在努力将这些EMR跨机构联系起来，并标准化治疗结果的大规模研究的表型定义，特别是在常规临床护理的背景下。尽管它的成功，基于EMR的药物基因组学研究往往受到其数据密集型的性质-这是耗时和昂贵的提取和整合数据从多个异构EMR数据库，大规模的药物基因组学研究。整合生物学和床边的信息学（i2 b2）是一个国家生物医学计算中心，位于合作伙伴医疗保健系统。I2 b2开发了一个可扩展的信息学框架，使临床研究人员能够重新利用现有的EMR数据进行临床和基因组发现。在这项研究中，我们将与i2 b2合作，将其信息学框架扩展到药物基因组学领域，提出以下具体目标：1）开发新的方法，从EMR中提取和建模药物暴露和结果信息，并将其与i2 b2 NLP组件集成; 2）构建本体工具，以规范和整合不同站点的药物基因组学数据; 3）进行已知和新的药物基因组学研究，以评估和完善目标1和2中开发的工具; 4）在药物基因组学研究人员中传播开发的信息学工具。

DESCRIPTION (provided by applicant): Rapid growth in the clinical implementation of large electronic medical records (EMRs) has led to an unprecedented expansion in the availability of dense longitudinal datasets for observational research. More recently, huge efforts have linked EMR databases with archived biological material, to accelerate research in personalized medicine. EMR- linked DNA biobanks have identified common and rare genetic variants that contribute to risk of disease. An appealing vision, which has not been extensively explored, is to use EMRs-linked biobanks for pharmacogenomic studies, which identify associations between genetic variation and drug efficacy and toxicity. The longitudinal nature of the data contained within EMRs make them ideal for quantifying drug outcome (both efficacy and toxicity). Efforts are already underway to link these EMRs across institutions, and standardize the definition of phenotypes for large-scale studies of treatment outcome, specifically within the context of routine clinical care. Despite its success, EMR-based pharmacogenomic studies are often hampered by its data-intensive nature -- it is time- consuming and costly to extract and integrate data from multiple heterogeneous EMR databases, for large-scale pharmacogenomic studies. The Informatics for Integrating Biology and the Bedside (i2b2) is a National Center for Biomedical Computing based at Partners Healthcare System. I2b2 has developed a scalable informatics framework to enable clinical researchers to repurpose existing EMR data for clinical and genomic discovery. In this study, we will collaborate with i2b2 to extend its informatics framework to the pharmacogenomics domain, by proposing the following specific aims: 1) Develop new methods to extract and model drug exposure and outcome information from EMR and integrate them with the i2b2 NLP components; 2) Build ontology tools to normalize and integrate pharmacogenomic data across different sites; 3) Conduct known and novel pharmacogenomic studies to evaluate and refine tools developed in Aim 1 and 2; and 4) Disseminate the developed informatics tools among pharmacogenomic researchers.